Business Context and Reporting Period
This Form 8-K Current Report was filed by CytoSorbents Corporation (Nasdaq: CTSO) on February 28, 2020. The filing details the approval of annual compensation packages for the company's executive officers by the Compensation Committee of the Board of Directors.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on executive compensation adjustments effective for the 2020 fiscal year.
Material Changes
The primary material change reported is the adjustment of executive compensation packages, including base salary increases and new equity awards, effective January 1, 2020, and granted on February 28, 2020.
- Phillip P. Chan, MD, PhD (CEO): Base salary increased by approximately 4.0% to $455,520. Received a cash bonus of $99,645, 80,000 stock options, and 60,000 restricted stock units (RSUs).
- Vincent J. Capponi (COO): Base salary increased by approximately 6.4% to $386,770. Received a cash bonus of $57,258, 68,000 stock options, and 54,100 RSUs.
- Kathleen P. Bloch (CFO): Base salary increased by approximately 8.2% to $349,460. Received a cash bonus of $50,876, 60,000 stock options, and 43,000 RSUs.
All stock options have a strike price of $6.03 (the closing price on the grant date) and a 10-year term. Cash bonuses were scheduled for payment in March 2020.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, market outlook, or specific risk factors. Management commentary is limited to stating that the adjustments were made following annual performance reviews and in recognition of the Company's 2019 performance and individual officer performance.
Investor Verification Checklist
- Verify the total dilution impact of the 248,000 stock options and 157,100 RSUs granted to executives.
- Confirm the cash outflow impact of the $207,779 in bonuses paid in March 2020.
- Review the vesting schedules: options vest quarterly over three years; RSUs vest annually over three years.
- Check subsequent filings for any changes in executive tenure or performance metrics tied to these awards.